Good Statistics Practice in the Drug Development and Regulatory Approval Process

Abstract

During the development and approval process of a new drug, the concept of good statistics practice (GSP) is necessarily implemented. GSP is a set of principles which assures the validity of the design and analysis of the intended studies conducted at various stages of the process of drug development and regulatory approval. GSP provides a fair assessment of the drug product with the desired accuracy, precision, and reliability. In essence, GSP not only concerns the validity of statistical inference regarding drug efficacy and safety, but also provides assurance of the proper identity, strength, quality, purity, and stability of the drug product. This paper describes regulatory requirements for statistics and the role of statistics in the drug development and regulatory process. The concept and importance of GSP are illustrated through some practical and/or regulatory statistical issues that commonly occur during the drug development and regulatory approval process.

Keywords

Code of Federal Regulations United States Pharmacopeia and National Formulary Good laboratory practice Good clinical practice Current good manufacturing practice Good research practice Good statistics practice

Get full access to this article

View all access options for this article.

References

USP/NF. The United States Pharmacopeia XXIII and the National Formulary XVIII. Rockville, MD: United States Pharmacopeidal Convention, Inc.; 1995.

FDA. Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics. Rockville, Maryland: Center for Drugs and Biologics, Food and Drug Administration; 1987.

FDA. Guideline for General Considerations for Clinical Evaluation of Drugs. Rockville, Maryland: Center for Drug Evaluation and Research, Food and Drug Administration; 1977.

FDA. Guideline for the Format and Content of the Clinical and Statistical Sections of an Application. Rockville, Maryland: Center for Drug Evaluation and Research, Food and Drug Administration; 1988.

FDA. Guidance on Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design. Rockville, Maryland: Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration; 1992.

ICH. Stability Testing of New Drug Substances and Products. Tripartite International Conference on Harmonization Guideline. International Conference on Harmonization; 1993.

Chow

. Statistical design and analysis of stability studies. Presented at the 48th Conference on Applied Statistics, Atlantic City, New Jersey: 1992.

Chow

Liu

. Statistical Design and Analysis in Pharmaceutical Science. New York, New York: Marcel Dekker, Inc.; 1995.

Nordbrock

. Statistical comparison of stability study designs. J Biopharm Stat. 1992;2:91–113.

10.

Chow

Liu

. Current issues in bioequivalence trials. Drug Inf J. 1995;29:795–804.

11.

Chow

Liu

. Meta-analysis for bioequivalence review. J Biopharm Stat. 1997;7(1):97–111.

12.

Chen

. Individual bioequivalence—a regulatory update. J Biopharm Stat. 1997;7(1):5–11.

13.

Wellek

. A comment on so-called individual criteria of bioequivalence. J Biopharm Stat. 1997;7:17–21.

14.

Endrenyi

. Some issues for the consideration of individual bioequivalence. J Biopharm Stat. 1997; 7:35–39.

15.

Liu

Chow

. Some thoughts on individual bioequivalence. J Biopharm Stat. 1997;7:41–48.

16.

Pledger

Hall

. Active control trials: do they address the efficacy issue? Proceedings of the Biopharmaceutical Section of the American Statistical Association; 1986:1–7.